

1 **Title:**

2 **Telmisartan and Insulin Resistance in HIV (TAILoR): Protocol for a Dose-Ranging**  
3 **Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the**  
4 **Reduction of Insulin Resistance in HIV-Positive Individuals on Combination**  
5 **Antiretroviral Therapy**

6

7 **Authors:** Sudeep P Pushpakom<sup>1,2,6</sup>, Claire Taylor<sup>3</sup>, Ruwanthi Kolamunnage-Dona<sup>3,4</sup>,  
8 Catherine Spowart<sup>3</sup>, Jiten Vora<sup>7</sup>, Marta García-Fiñana<sup>4</sup>, Graham J Kemp<sup>8</sup>, John Whitehead<sup>5</sup>,  
9 Thomas Jaki<sup>5</sup>, Saye Khoo<sup>6</sup>, Paula Williamson<sup>3,4</sup>, Munir Pirmohamed<sup>1,2,6</sup>.

10

11

12 **Affiliations:**

13 <sup>1</sup>The Wolfson Centre for Personalised Medicine, Department of Molecular and Clinical  
14 Pharmacology, University of Liverpool, Liverpool, UK.

15 <sup>2</sup>MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.

16 <sup>3</sup>Clinical Trials Research Centre, University of Liverpool, Liverpool, UK.

17 <sup>4</sup>Department of Biostatistics, University of Liverpool, Liverpool, UK.

18 <sup>5</sup>Department of Mathematics and Statistics, Lancaster University, Lancaster, UK

19 <sup>6</sup>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

20 <sup>7</sup>The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.

21 <sup>8</sup>Magnetic Resonance and Image Analysis Research Centre, University of Liverpool,  
22 Liverpool, UK.

23

24 **Corresponding author:**

25 Professor Munir Pirmohamed, The Wolfson Centre for Personalised Medicine, Department  
26 of Molecular and Clinical Pharmacology, University of Liverpool, Block A, Waterhouse  
27 Buildings, 1-5 Brownlow Street, Liverpool, L69 3GL, UK.

28 Email: [munirp@liv.ac.uk](mailto:munirp@liv.ac.uk)

29 Tel: 01517945549

30

31 **Keywords:** Insulin resistance; HIV; Antiretroviral Therapy, Highly Active; Metabolic  
32 Diseases; Telmisartan.

33

34 **Word Count:** 6042

1 **Abstract:**

2 **Introduction:** Telmisartan, an angiotensin receptor blocker, has beneficial effects on insulin  
3 resistance and cardiovascular health in non-HIV populations. This trial will evaluate whether  
4 telmisartan can reduce insulin resistance in HIV-positive individuals on combination  
5 antiretroviral therapy (cART).

6 **Methods and Analysis:** This is a phase II, multi-centre, randomised, open-labelled, dose-  
7 ranging trial of telmisartan in 336 HIV-positive individuals over a period of 48 weeks. The trial  
8 will use an adaptive design to inform the optimal dose of telmisartan. Patients will be  
9 randomised initially 1:1:1:1 to receive one of the 3 doses of telmisartan (20, 40 and 80mg) or  
10 no intervention (control). An interim analysis will be performed when half of the planned  
11 maximum of patients have been followed up for at least 24 weeks. The second stage of the  
12 study will depend on the results of interim analysis. The primary outcome measure is a  
13 reduction in insulin resistance (as measured by HOMA-IR) in telmisartan treated arm(s) after  
14 24 weeks of treatment in comparison with the non-intervention arm. The secondary outcome  
15 measures include changes in lipid profile; body fat redistribution (as measured by MRI);  
16 plasma and urinary levels of various biomarkers of cardiometabolic and renal health at 12,  
17 24 and 48 weeks. Serious adverse events will be compared between different telmisartan  
18 treated dose arm(s) and the control arm.

19 **Ethics and dissemination:** The study, this protocol and related documents have been  
20 approved by the National Research Ethics Service Committee North West – Liverpool  
21 Central (Ref: 12/NW/0214). On successful completion, study data will be shared with  
22 academic collaborators. The findings from TAILoR will be disseminated through peer-  
23 reviewed publications, at scientific conferences, the media, and through patient and public  
24 involvement.

25 **Study Registration No.:** Clinical Trial Authorisation reference is 04196/0024/001-0001;  
26 EUDRACT number: 2012-000935-18; ISRCTN No. is 51069819.  
27 Information about the study is also available at <http://www.tailortrial.org.uk/>

28  
29  
30  
31  
32  
33  
34  
35  
36  
37

1 **Strengths and Limitations:**

- 2       • This clinical trial will evaluate whether telmisartan can reduce insulin resistance in  
3       HIV-positive individuals on combination antiretroviral therapy; this may lead to the  
4       repositioning of telmisartan to treat metabolic disease.
- 5       • The trial will use an adaptive design to inform the optimal dose of telmisartan for  
6       reduction of insulin resistance. This design also allows stopping of the trial midway if  
7       none of the doses show a statistically significant effect after the interim analysis  
8       thereby reducing the duration of trial and related costs.
- 9       • The trial is assessing a surrogate marker (insulin resistance) as an outcome measure  
10      in this trial. Despite the fact there is a good relationship between insulin resistance  
11      and cardiovascular health, this represent a limitation of the trial.

12  
13  
14  
15

## 1 BACKGROUND AND RATIONALE

2 Combination antiretroviral therapy (cART) is the mainstay for treatment of HIV and has  
3 dramatically improved the morbidity and mortality associated with HIV, turning it into a  
4 chronic disease. However, cART, together with the virus itself, can result in various  
5 metabolic complications, including metabolic syndrome, type 2 diabetes (T2DM) and an  
6 increased risk of cardiovascular disease (CVD)[1]. These metabolic complications  
7 associated with cART also occur with HIV lipodystrophy (also called fat redistribution  
8 syndrome), a clustering of morphologic and metabolic abnormalities comprising peripheral  
9 fat loss (lipoatrophy), visceral lipid hypertrophy, insulin resistance and dyslipidemia[2], which  
10 also increases the risk of CVD[3].

11  
12 The prevalence of metabolic syndrome is high in cART treated HIV-infected patients (ranges  
13 from 11.2 – 45.4% in different HIV populations)[4]; the HIV DAD cohort (n=33,347) found the  
14 prevalence of metabolic syndrome to increase from 19.4% to 41.6% over a 6-year period  
15 with patients having metabolic syndrome showing a 4-fold increase in the incidence of T2DM  
16 and a 2-3 fold increased risk of developing CVD[5]. These results have been confirmed by  
17 the Multicenter AIDS Cohort Study (n=1278)[6] and a more recent analysis of the DAD  
18 cohort[7]. Cumulative exposure to cART also results in an increased risk of myocardial  
19 infarction with both protease inhibitors[8] (PIs) and nucleoside reverse transcriptase  
20 inhibitors[9] (NRTIs) and results in intima-media thickness and an increase in the prevalence  
21 of carotid lesions[10].

22  
23 Insulin resistance, a key feature of HIV lipodystrophy and metabolic syndrome, has been  
24 described as central to cardiometabolic disease and is considered to be an important link  
25 between features of metabolic syndrome, obesity, dyslipidemia, T2DM and CVD[11]. *In vitro*  
26 studies[12] and single drug studies in healthy individuals[13] and HIV-infected patients[14  
27 15] have shown that PIs and NRTIs cause insulin resistance. The prevalence of insulin  
28 resistance in cART-treated HIV-infected patients ranges from 10-37%[14-16] indicating a  
29 significant role for cART in its development. Several mechanisms have been suggested to  
30 be responsible for cART-induced insulin resistance; these include cART-induced inhibition of  
31 adipocyte differentiation[17], increased secretion of adipokines such as IL-6 and TNF- $\alpha$ [18],  
32 and impairment of the insulin signalling pathway[12].

33  
34 Clinical intervention to arrest or reverse cART-associated insulin resistance has been  
35 suggested as a strategy to reduce the incidence of T2DM and CVD in HIV-positive patients.  
36 Insulin sensitizers such as thiazolidinediones and metformin have been trialled but results  
37 from randomised clinical trials in HIV patients have shown mixed results[19 20]. Moreover,

1 the associated adverse effects may limit their use in HIV-infected patients[21 22]. Therefore  
2 there is a need for novel clinical interventions with proven safety profile that can reduce  
3 cART-induced insulin resistance in HIV-infected individuals.

4  
5 Some angiotensin receptor blockers (ARBs) have a beneficial effect on insulin resistance  
6 and T2DM, owing to their action on the renin-angiotensin system and partial agonist activity  
7 at PPAR $\gamma$ , an important regulator of adipocyte function. Telmisartan shows maximal potency  
8 on PPAR $\gamma$  when compared to other ARBs and has been reported to reduce insulin  
9 resistance in several *in vitro*[23 24], animal[25 26] and clinical studies[27-30]. Telmisartan  
10 also improves adiponectin levels, an important metabolic marker of insulin resistance and  
11 atherosclerotic disease, lipid control, and has favourable effects on fasting serum insulin and  
12 high sensitivity C-Reactive Protein[27] (hs-CRP; a marker of cardiovascular disease).  
13 Telmisartan has also been shown to reduce visceral, but not subcutaneous fat accumulation,  
14 in patients with metabolic syndrome[31 32]. Importantly, telmisartan already has a license for  
15 cardiovascular protection in a broad group of at-risk patients (ONTARGET trial; 120,000  
16 patient-years of follow-up)[33].

17  
18 By contrast to the non-HIV population, the effect of telmisartan on insulin resistance in  
19 cART-treated HIV-positive patients has not been assessed. Using *in vitro* adipocyte models,  
20 we (Pushpakom, unpublished) and others[34] have shown that telmisartan partially reverses  
21 the anti-adipogenic effects of antiretrovirals. Our trial has therefore been designed to  
22 address this. Furthermore, although the dose-response relationship of telmisartan in  
23 hypertension is well known, whether this would also be similar in reducing insulin resistance  
24 is unclear. Our *in vitro* study in fact suggested that there might be a non-monotone (bell  
25 shaped) relationship of telmisartan on markers of adipocyte health. We have therefore  
26 utilised an adaptive trial design during the initial stage of the study to carefully assess the  
27 dose-response relationship of telmisartan *in vivo*.

## 28 29 **OBJECTIVES**

30 The primary objective of the trial is to determine the effect of telmisartan on insulin  
31 resistance in HIV-positive individuals on cART using Homeostatic Model Assessment –  
32 Insulin Resistance (HOMA-IR). HOMA-IR is a measurable, validated surrogate marker of  
33 insulin resistance[35].

34  
35 The secondary objectives include assessing the optimal dose of telmisartan that can  
36 significantly reduce insulin resistance; evaluation of tolerability of telmisartan in HIV patients

1 and mechanistic evaluation of the metabolic effects of telmisartan. The mechanistic  
2 evaluation of telmisartan will explore longitudinal changes in plasma markers that are  
3 important indicators of cardiometabolic health (adiponectin, IL-6, resistin, TNF $\alpha$ , hs-CRP and  
4 lipids) at different time points; it will also utilise magnetic resonance imaging (MRI) and  $^1\text{H}$   
5 magnetic resonance spectroscopy (MRS) to assess the effect of telmisartan on total body fat  
6 and intrahepatic and intramyocellular triglyceride content, respectively. The MRI/MRS  
7 evaluation will be limited to a subset of participants who are recruited locally.

8  
9 Telmisartan is known to possess renoprotective effects[36 37]; in addition to the above  
10 objectives, the study will also assess its effects on the kidney using urinary markers of renal  
11 injury (conventional markers such as creatinine, urea, total protein and novel biomarkers  
12 such as KIM-1, NGAL, and RBP).

## 14 **TRIAL DESIGN**

15  
16 This study is a phase II, multi-centre, randomised, open-labelled, dose-ranging trial of  
17 telmisartan in HIV-positive individuals over a period of 48 weeks. The sample size for the  
18 study is 336 (see Sample size calculation) but a total of 370 patients will be recruited to  
19 participate in this study to account for patient withdrawals (estimated to be 10%).

20  
21 The optimal dose of telmisartan that elicits the desired response is not known; hence an  
22 adaptive design is utilised for this study. The first stage of the study will be dose-ranging  
23 where patients will be randomised 1:1:1:1 to receive one of 3 doses of telmisartan (20, 40  
24 and 80mg) or no intervention (control). An interim analysis will be performed when half of  
25 the planned maximum of 336 patients have been followed up for at least 24 weeks. The  
26 second stage of the study will depend on the results of interim analysis, which could be one  
27 of the three outcomes listed below:

28 i) One or more active dose groups are substantially more effective than control; this will lead  
29 to stopping of the study and the corresponding dose(s) will be taken directly into phase III.

30 ii) no dose shows sufficient promise at the interim analysis; this will also lead to stopping of  
31 the study.

32 iii) at least one of the doses shows some improvement over control at interim analysis; this  
33 will lead to a second stage where that dose(s) will be followed up along with the control for a  
34 further 24 weeks (total: 48 weeks). Additional patients will also be recruited to these dose(s)  
35 and control. If at the final analysis, a large enough reduction in 24 week HOMA-IR score is  
36 found, the corresponding active dose will be recommended for phase III.

37

1 In the telmisartan 40mg and 80mg arms, dose titration will be undertaken over 2–4 weeks in  
2 order to step-up to the allocated dose (as per the Summary of Product Characteristics;  
3 SPC), or else the maximum tolerated dose if the target is not achieved. All assessments will  
4 be carried out at baseline and at weeks 12, 24, and 48 post treatment with telmisartan, as  
5 well as in the control arm. For those who participate in the MRI/MRS sub-study, assessment  
6 will be at baseline and 24 weeks. The study flow diagram is given in Figure 1.

7

8 The Clinical Trials Research Centre (CTRC), University of Liverpool, is the co-ordinating  
9 centre for this study (<http://www.liv.ac.uk/translational-medicine/research/ctrc/about/>).

10

## 11 **PATIENT RECRUITMENT**

12

### 13 **Identification of eligible patients**

14

15 Patients who are eligible for inclusion into the trial will be identified and recruited through the  
16 HIV speciality centres located in the UK and has agreed to participate in the study. These  
17 HIV speciality centres are part of the secondary care which are mostly based in an urban  
18 setting. Participants will be identified by the clinical team at each centre via a search of the  
19 patient database(s) either electronically or manually or clinic list review to find potentially  
20 eligible patients. The inclusion and exclusion criteria are detailed in Table 1.

21

### 22 **Consent procedure**

23

24 At the routine clinic visit, eligible patients are informed of the study by a member of the  
25 clinical team or research staff. A Patient Information Sheet and instructions on how to  
26 proceed if they are interested in taking part will be provided by the research nurse. All  
27 patients will be provided with a full explanation of the trial and given sufficient time to  
28 consider their decision before obtaining informed written consent. In consenting to the trial,  
29 patients are consented to trial treatment, follow-up and data collection. Patients are free to  
30 withdraw consent at any time without providing a reason. Follow-up of these patients will be  
31 continued through the trial research nurses and the lead investigator at each centre unless  
32 the participant explicitly also withdraws consent for follow-up.

33

34

35

36

37

1 **Table 1: Inclusion and exclusion criteria**

<b>Inclusion criteria</b>
1. Adult (age 18 or above) HIV-positive individuals receiving antiretroviral therapy for at least 6 months. The antiretroviral therapy may contain: <ul style="list-style-type: none"> <li>➤ a boosted protease inhibitor (LPV/r, ATV/r, DRV/r, FAPV/r, SQV/r)</li> <li>➤ and/or efavirenz, rilpivirine, or etravirine</li> </ul> <i>The backbone can be based on N(t)RTI, raltegravir or maraviroc. Patients on protease inhibitor monotherapy will be included if they meet other criteria. Patients on nevirapine or dolutegravir regimens, without concomitant boosted PIs, should not be included. Additionally, patients on elvitegravir which is administered in combination with cobicistat (as Stribild) should not be recruited.</i>
2. Ability to give informed consent
3. Willingness to comply with all study requirements
<b>Exclusion criteria</b>
1. Pre-existing diagnosis of type 1 or 2 diabetes (Fasting glucose > 7.2 mmol/L or HbA1c ≥ 6.5% [48 mmol/mol] or abnormal OGTT or random plasma glucose ≥ 11 mmol/l)
2. Patients known to have consistently low blood pressure (pre-existing hypotension; A reading below a threshold of 100/60 mm Hg on three separate occasions)
3. Patients with renal disease (eGFR<60 in the 6 months preceding randomisation)
4. Patients with known untreated renal artery stenosis
5. Patients with cholestasis, biliary obstructive disorders or severe hepatic impairment.
6. Patients with evidence of an active, chronic hepatitis C infection
7. Patients who are on unboosted ATV
8. Patients who are on/ have been on hormone therapy, anabolics and insulin sensitisers within 6 months preceding randomisation. Patients on hormonal contraception are eligible.
9. Patients who are already on/ have been on other ARBs, ACE inhibitors, or direct renin inhibitors within 4 weeks preceding randomisation.
10. Those with suspected poor compliance
11. Pregnant or lactating women
12. Women of childbearing age unless using reliable contraception e.g. coil, barrier method, hormonal contraceptive that does not interact with their antiretroviral therapy
13. Co-enrolment in other drug trials
14. Patients who have participated in a trial of an IMP likely to influence insulin sensitivity, plasma insulin, glucose levels or plasma lipid levels within 6 months preceding randomisation.
15. For the sub-cohort of patients undergoing MRI/MRS, normal MR exclusion criteria will apply (See Body fat distribution sub-study).

2 LPV/r: lopinavir/ritonavir; ATV: atazanavir; DRV: darunavir; FAPV: fosamprenavir; SQV: saquinavir; N(t)RTI:  
3 nucleoside (nucleotide) reverse transcriptase inhibitors; PI: protease inhibitor; HbA1c: glycated haemoglobin;  
4 OGTT: oral glucose tolerance test; eGFR: estimated glomerular filtration rate; ARB: angiotensin receptor  
5 blockers; ACE: angiotensin converting enzyme; IMP: investigational medicinal product.  
6  
7

8 **Baseline Assessments**

9  
10 Once informed consent has been obtained from the patient, they will be booked in for a  
11 baseline assessment visit within 30 days of giving consent. The patient will be advised to  
12 arrive fasting when reporting for the baseline assessment. The research team will conduct  
13 the baseline assessments and complete the eligibility and baseline case report form (CRF)  
14 during the baseline assessment visit. The baseline assessments include fulfilment of  
15 eligibility criteria; recording demographic details; full medical and drug history; body weight



1 and vital signs; and waist/thigh circumference. A urine pregnancy test is offered for females  
2 of childbearing potential since telmisartan is not recommended during the first trimester of  
3 pregnancy and is contraindicated during the second and third trimesters of pregnancy due to  
4 its teratogenic potential. However a refusal to undertake a pregnancy test will not preclude  
5 trial entry. Blood samples (for plasma, serum and DNA) and urine will also be collected from  
6 each patient at the time of baseline screening. Table 2 details the schedule of study  
7 assessments conducted.

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

1 **TABLE 2: Schedule of Study Procedures**

2

Time	Pre T0	T0	T+2 week	T+4 weeks	T+12 weeks	T+24 weeks	T+48 weeks	
	At each recruitment site	Randomisation/ Baseline*	Dose titration - 40/80mg arms (dose given 40mg)	Dose titration for 80mg arm (dose given 80mg)	Follow-up	Follow-up	End of treatment	Premature withdrawal of consent
Database search to identify potential participants or clinic list review	X							
Information sheet provided to patient	X							
Signed Informed consent		X						
Assessment of Eligibility Criteria by a medically qualified person		X						
Review of Medical History (including collection of most recent blood test results for Urea & electrolytes, eGFR, liver function, diabetes screening etc)		X**					X	X
Review of Concomitant Medications		X	X	X	X	X	X	X
Urine pregnancy test		X			X	X		
Randomisation		X						
Study Intervention		X	X	X	X	X		
Compliance with study intervention - patient diaries & pill counting			X	X	X	X	X	
Physical Exam - Complete		X						
Physical Exam - Symptom-Directed			X	X	X	X	X	X
Height		X						
Weight		X			X	X	X	X
Waist/thigh circumference		X			X	X	X	X
Heart rate, blood pressure		X	X	X	X	X	X	X
Collection of 3 fasting blood samples for bioanalysis		X			X	X	X	X
Collection of urine sample		X			X	X	X	X
Assessment of Adverse Events			X	X	X	X	X	X
Consent for sub-study		X						
MRI/MRS scan for sub-study		X				X		

3 (X) – As indicated/appropriate.

4 \*Baseline assessment and randomisation visit should be within 30 days of the patient giving consent.

5 \*\* liver function and diabetes screening result only to be collected at baseline.

6

7 **RANDOMISATION**

8

1 Participants will be randomised to receive telmisartan 20mg, 40mg, 80mg or control (no  
2 intervention) in a 1:1:1:1 ratio once a) eligibility criteria have been fulfilled; b) fully informed  
3 written consent has been obtained; and c) baseline assessments have been completed.  
4 Participants will be randomised using a bespoke secure (24-hour) web based randomisation  
5 programme controlled centrally by the CTTC, University of Liverpool. For each recruiting  
6 centre, randomisation will be stratified by ethnicity (Black and Non-Black) where ethnicity is  
7 determined by self-categorisation using the NHS ethnicity codes. Centres will be provided  
8 with emergency back-up randomisation envelopes to be used in the event of a system failure  
9 or when a system failure cannot be resolved in a reasonable timeframe. Patients may only  
10 be randomised into the study by an authorised member of staff at the study site as detailed  
11 on the delegation log. Participants may only be randomised into the study once.

12

### 13 **TRIAL INTERVENTIONS**

14

15 Telmisartan is an angiotensin receptor antagonist indicated for clinical use as an  
16 antihypertensive agent. It is also used to reduce cardiovascular events in patients who are at  
17 risk. However, the current trial uses telmisartan outside its licensed indications.

18

19 At the onset of the trial, telmisartan was under patent (Boehringer Ingelheim GmbH;  
20 Micardis); however during the course of the trial, the patent expired and several  
21 manufacturers started marketing generic telmisartan, which were then also used in the trial,  
22 but the trial will continue to use Micardis SPC as the reference SPC. Telmisartan used in this  
23 trial is sourced via usual local NHS procurement arrangements.

24

25 Telmisartan tablets are available in 20, 40, or 80mg doses and therefore fits in with the dose-  
26 ranging to be used in the trial prior to interim analysis. In most cases, the participant is  
27 provided their required dose in one tablet. Telmisartan tablets are for once-daily oral  
28 administration and should be taken with liquid, with or without food. The CRFs will be used  
29 to record which brand has been dispensed to the participant. Telmisartan is stored as per  
30 the manufacturer's SPC.

31

32 For each randomised patient, treatment is for a maximum period of 48 weeks. The principal  
33 investigator or delegated other will issue a prescription based on the patient's randomisation  
34 status and the trial treatment can start immediately after randomisation. For the three  
35 treatment arms, treatments will be dispensed at the appropriate doses at baseline, at 12  
36 weeks and then at 24 weeks, unless interruption or discontinuation is warranted. Wherever  
37 titration of dose is required, the treatment starts with 20mg and then titrated upwards over a

1 period of 2 (for 40mg) or 4 weeks (for 80mg dose). At 48 weeks, administration of trial  
2 treatments will be stopped and any unused medications will be returned to pharmacy for  
3 disposal via their local procedures. There is a two week attendance window either side of  
4 each of the follow up visits and a four day window on either side of the titration visits.

5  
6 Since the results of the interim analysis decide the design of stage II of the trial, those  
7 patients who are on a dose that is not taken forward to Stage II will be asked to stop taking  
8 the medication completely. These patients will continue to be monitored for any adverse  
9 events for a period of 7 days (wash out period for telmisartan) after which they will no longer  
10 be part of the trial and will return to routine care. For those who are on trial arms whose  
11 dose(s) are taken forward to Stage II, they will be asked to continue on the same dose for a  
12 further 24 weeks. Since treatment is not stopped between Stages I and II, some participants  
13 may receive up to a maximum of 48 weeks trial treatment before the results of the interim  
14 analysis are known. For patients recruited after the results of interim analysis are known,  
15 they will be randomised equally to the non-intervention (control) arm and the remaining  
16 telmisartan dose arm(s).

17  
18 Dose modifications will be allowed in those who are randomised to a particular dose arm but  
19 do not tolerate that dose. The patient will be allowed to continue on the nearest dose  
20 tolerated. Those who show adverse effects as a result of the trial intervention or due to the  
21 HIV therapy may be withdrawn from the trial treatment. The decision to interrupt or  
22 discontinue trial therapy is at the discretion of the treating physician using their informed  
23 clinical opinion. Any changes will be documented in the CRF along with the justification for  
24 those changes. Patients withdrawn will be asked to allow continuation of scheduled  
25 evaluations, complete an end-of-study evaluation if appropriate and be given appropriate  
26 care under medical supervision until the symptoms of any adverse event resolve or the  
27 patient's condition becomes stable. Follow-up of patients withdrawn will be continued  
28 through the trial research nurses and the lead investigator at each centre unless the  
29 participant explicitly also withdraws consent for follow-up. Data up to the time of withdrawal  
30 will be included in the analyses unless the patient explicitly states that this is not their wish.

### 31 32 **PATIENT FOLLOW-UP**

33  
34 Apart from the dose-titration visits for participants in 40 and 80mg arms, follow-up visits will  
35 be designed to fit with routine hospital visits where possible. The study will also allow a two  
36 week window either side of the scheduled follow-up visit date to ensure flexibility. Individual  
37 patients will be sent reminders on follow-up visit by the research nurse provided they have

1 agreed to it. If any of the trial patients are lost to follow up, contact will be attempted through  
2 the research nurse and lead investigator at each centre. Wherever possible, information on  
3 the reason for loss to follow-up will be recorded.

4  
5

6 **OUTCOMES AND ASSESSMENTS**

7

8 Efficacy of trial treatments will be assessed throughout the period of the study. The primary  
9 outcome measure is a reduction in insulin resistance (as measured by HOMA-IR) in  
10 telmisartan treated arm(s) after 24 weeks of treatment in comparison with the non-  
11 intervention arm. Fasting plasma and serum samples will be collected from each participant  
12 at baseline and at follow-up visits (weeks 12, 24 and 48) and stored under appropriate  
13 conditions locally. Biochemical analyses will be carried out centrally in an accredited clinical  
14 laboratory. Fasting plasma glucose will be measured by standard clinical methods and  
15 serum insulin will be measured by an electrochemiluminescence immunoassay using Cobas  
16 C Analyser (Roche Diagnostics, Switzerland). HOMA-IR will be calculated using the  
17 equation: [Fasting serum insulin (mU/l) × fasting plasma glucose (mmol/l)]/ 22.5. The  
18 secondary outcome measures are detailed in Table 3. Serum and urine biomarker analyses  
19 and DNA extraction will be performed centrally using Human Multiplex ELISA (Millipore) on a  
20 BioPlex 200 System (BioRad) and Chemagic Magnetic Separation Module I (MSM I)  
21 respectively.

22

23 **Table 3: Secondary outcome measures**

1. Change in lipid profile (total cholesterol, triglycerides, LDL-c and HDL-c) at weeks 12, 24 and 48 between telmisartan treated arm(s) and the control arm.
2. Change in body fat redistribution as measured by MRI/MRS at 24 weeks between telmisartan treated arm(s) and control arm (See sub-study).
3. Change in plasma concentrations of biomarkers (adiponectin, lipin1, IL-6, TNF-α, resistin and hs-CRP) at 12, 24 and 48 weeks between telmisartan treated arm(s) and control arm.
4. Change in insulin resistance, measured longitudinally at weeks 12 and 48, in telmisartan treated arm(s) in comparison with the control arm.
5. Change in urinary biomarker levels at 12, 24 and 48 weeks between telmisartan treated arm(s) and the control arm.
6. Difference in expected and unexpected serious adverse events between different telmisartan treated dose arm(s) and the control arm at weeks 24 and 48.

24 LDL-c: low density lipoprotein-cholesterol; HDL-c: high density lipoprotein-cholesterol; IL-6: interleukin-6; TNF-α:  
25 tumour necrosis factor- α; hs-CRP: high sensitive, C-reactive protein.

26

27 **Assessment of Compliance with Study Treatment/s**

28

29 All participants on intervention arms are given a treatment diary to record their daily  
30 treatment compliance. Compliance with the study treatment will be ascertained based on

1 what is recorded in the treatment diary and by recording the number of pills remaining in the  
2 packs.

3

#### 4 **Body Fat Redistribution Sub-study**

5

6 A sub-study will be undertaken only for patients recruited from the North West of UK to  
7 assess whether telmisartan results in any changes in the total body adipose content and  
8 intrahepatic and intramyocellular lipid content. This will be assessed at baseline and at 24  
9 weeks by MRI and <sup>1</sup>H MRS in an on-site MRI research facility. Patients recruited will be  
10 given a separate patient information sheet and consent form containing information on the  
11 sub-study and requirements for MRI/MRS. Participants will be allowed to withdraw from the  
12 sub-study anytime but remain in the main study. Only patients who consent to take part in  
13 the main study and satisfy the normal MR exclusion criteria (normal MR exclusion criteria  
14 include patients using pacemakers, cochlear implants, piercings, metal in the head or  
15 elsewhere in the body, and those who suffer from claustrophobia) will be included in the sub-  
16 study. MRI of the total body adipose content will be undertaken on a Siemens 1.5T  
17 Symphony scanner (Siemens, Erlangen Germany) using well-established methods[38]. The  
18 MR images will be analysed to obtain volume estimates of total body subcutaneous, total  
19 internal, subcutaneous abdominal, and intra-abdominal adipose tissue. In the same sub-  
20 cohort of patients, liver and skeletal muscle <sup>1</sup>H MR spectra will be acquired using the  
21 Siemens body coil and Siemens CP extremity coil respectively using established  
22 methods[39]. Analysis of all imaging data will be conducted centrally.

23

#### 24 **SAMPLE SIZE CALCULATION**

25 The primary response from each patient is the difference between the baseline HOMA-IR  
26 score and their HOMA-IR score at 24 weeks. The design has been constructed under the  
27 assumption that for all patients this response is normally distributed with a common standard  
28 deviation,  $\sigma$ .

29

30 The sample size calculation is based on a one-sided type I error of 5% and a power of 90%.  
31 If there is no difference between the mean response on any treatment and that on control,  
32 then a probability of 0.05 is set for the risk of erroneously ending the study with a  
33 recommendation that any treatment be tested further. For the power, we adopt a  
34 generalisation of this power requirement to multiple active treatments due to Dunnett[40].  
35 Effect sizes are specified as the percentage chance of a patient on active treatment  
36 achieving a greater reduction in HOMA-IR score than a patient on control as this  
37 specification does not require knowledge of the common standard deviation,  $\sigma$ . The

1 requirement is that, if a patient on the best active dose has a 65% chance of a better  
2 response than a patient on control, while patients on the other two active treatments have a  
3 55% chance of showing a better response than a patient on control, then the best active  
4 dose should be recommended for further testing with probability  $1 - \beta = 0.90$ . A 55% chance  
5 of achieving a better response on active dose relative to control corresponds to a reduction  
6 in mean HOMA-IR score of about a sixth of a standard deviation ( $0.178\sigma$ ) while the clinically  
7 relevant effect of 65% corresponds to a reduction of about half a standard deviation  
8 ( $0.545\sigma$ ). The critical values for recommending that a treatment is taken to further testing at  
9 the interim and final analyses (2.782 and 2.086), have been chosen to guarantee these  
10 properties using a method described by Magirr et al[41], generalising the approach of  
11 Whitehead and Jaki[42].

12

13 The maximum sample size of this study is 336 evaluable patients, although the use of the  
14 interim analysis may change the required sample size. The study will recruit additional  
15 patients to account for an anticipated 10% drop-out rate.

16

### 17 **Interim Monitoring and Analyses**

18 An interim analysis will take place once the primary endpoint is available for at least 42  
19 patients on each arm (i.e. half of the planned maximum of 336 patients). The sample  
20 standard deviation pooled across all four arms is used to construct test statistics expressing  
21 the advantage of each of the three active treatments over control. The analysis will be  
22 proceeding as follows:

- 23 i. If the largest test statistic exceeds 2.782 the study will be stopped and the corresponding  
24 dose will be recommended for further testing.
- 25 ii. If any active dose shows no improvement over control (i.e. has a negative test statistic)  
26 that active dose will be dropped.
- 27 iii. If no active dose shows an improvement over control the study will be stopped and no  
28 significant improvement over control will be claimed.
- 29 iv. If some improvement over control is detected for at least one dose (i.e. at least one test  
30 statistic is between 0 and 2.782), the study will progress to the second stage.

31

32 At the interim analysis, doses may be dropped from the trial, or the trial may be stopped  
33 altogether. Consequently, the required sample size when the decision is reached could be  
34 smaller than the maximum stated number of 336 patients. The values 168 (if the study is  
35 stopped following interim analysis), 252 (if one active dose arm is promoted to the second  
36 stage), 294 (if two active dose arms are promoted to second stage) and 336 (if all three  
37 active dose arms are promoted to second stage) are possible. The reduced sample sizes

1 refer to the numbers of patients with 24 week HOMA-IR scores which are included in the  
2 analysis. Evaluation of patient withdrawal rate will be carried out and the sample size will be  
3 adjusted accordingly. There will be additional patients who have been recruited during the 24  
4 weeks prior to extracting the data for interim analysis and their number will depend on the  
5 recruitment rate achieved. A decision to discontinue recruitment, in all patients or in selected  
6 subgroups, will be made on the basis of results from the interim analysis, by the Independent  
7 Data and Safety Monitoring Committee (IDSMC).

## 9 **STATISTICAL ANALYSIS**

### 11 **Primary Outcome Analysis**

12 Three different doses of the intervention will be evaluated against the control in stage 1 of  
13 the study and an interim analysis will take place that will allow ineffective doses to be  
14 eliminated quickly while a dose showing a positive effect can be taken forward. The sample  
15 standard deviation pooled across all four arms will be determined and used to construct test  
16 statistics expressing the advantage of each of the active treatments over control. These  
17 statistics will be adjusted for the stratification factor (Black and Non-Black). The largest of  
18 these test statistics will be compared to the interim critical value (2.782) and proceed as  
19 discussed above at the interim analysis. At the final analysis, if the largest comparative test  
20 statistic exceeds the final critical value (2.086) then this dose would be recommended for  
21 further study. Adjustments can be made to allow for any discrepancies between target and  
22 actual sample sizes while still preserving the one-sided type I error rate at 0.05.

### 24 **Secondary outcome analysis**

25 Linear mixed effect models will be used to analyse secondary and mechanistic outcomes.  
26 The evaluation of beneficial and adverse biomarkers in relation to insulin resistance will be  
27 examined using joint modelling approach[43 44] accounting for informative loss to follow up  
28 or censoring. Structural equation models[45] will be used to assess the inter-relationship  
29 between multiple biomarkers over effect of treatment while accounting for time-varying  
30 confounders. Mechanistic outcomes such as change in body fat, liver and muscle fat  
31 distribution will be analysed using a multiple linear regression model. Differences will be  
32 considered significant at  $P < 0.05$ . Differences between the groups will be estimated with  
33 95% confidence intervals.

## 34 **SAFETY REPORTING**

35 CTRC will be notified of all serious adverse reactions (SAR), serious adverse events (SAE)  
36 and suspected unexpected serious adverse reactions (SUSARs) within 24 hours of the local  
37 site becoming aware of the event. The CTRC will notify the MHRA and main Research



1 Ethics Committee (REC) of all SUSARs occurring during the study on behalf of the chief  
2 investigator according to the following timelines; fatal and life-threatening within 7 days of  
3 notification and non-life threatening within 15 days. It will also submit an annual report of all  
4 SAEs to the sponsor, MHRA and the main REC and will provide the IDSMC with listings of  
5 all SAEs on an on-going basis. The study may be prematurely discontinued on the basis of  
6 new safety information, or for other reasons given by the IDSMC and/or Trial Steering  
7 Committee (TSC), sponsor, or REC concerned. All investigators will be informed of all  
8 SUSARs occurring throughout the study. The assignment of the severity/grading of adverse  
9 events will be made by the investigator responsible for the care of the participant using the  
10 Division of AIDS Table for Grading the Severity of Adult and Paediatric Adverse Events  
11 Version 1.0 (2009) definitions[46]. The CTRC will monitor SAE and ADR reporting rates  
12 across sites during the course of the trial and if any inconsistencies noted, this will be  
13 investigated and additional training will be provided.

14

### 15 **Reporting of Pregnancy**

16 Female study participants of childbearing potential will be offered a pregnancy test as part of  
17 the trial screening process and at weeks 12 and 24. Any pregnancy which occurs during the  
18 study will be reported as a SAE to the CTRC within 24 hours of the site becoming aware of  
19 its occurrence and the participant will be instructed immediately to stop taking study drugs.  
20 All pregnancies that occur during treatment need to be followed up until after the outcome.  
21 The investigator will discuss the risks of continuing with the pregnancy and the possible  
22 effect to the foetus with the participant.

23

### 24 **ETHICAL CONSIDERATIONS**

25

26 The conduct of this study will be in accordance with the Declaration of Helsinki, 1964 and  
27 later revisions.

28

29 The main ethical issue is the potential allocation of participants to less effective treatment  
30 arms. In stage 1 of the trial, a quarter of the patients will be allocated to the non-intervention  
31 control arm; it is also likely that some of the intervention arms could be found to be less  
32 effective during the interim analysis and hence, be dropped. However, these comparator  
33 arms are necessary for the identification of a positive drug effect in the treatment arm(s) and  
34 its optimal dose. This does not have any impact on the control of HIV infection since the  
35 intended use of telmisartan in this patient population is only as an adjuvant drug and not as  
36 the primary drug to treat HIV infection.

37

1 Telmisartan is an antihypertensive drug, and thus there is a possibility that some of the  
2 participants randomised to the higher doses may experience hypotension. The eligibility  
3 criteria aim to exclude those who consistently show hypotension; moreover, the prevalence  
4 of telmisartan-induced hypotension in normotensive individuals has been found to be rare in  
5 previous studies[47 48]. However, the trial will take adequate precautions such as routine  
6 blood pressure monitoring to address this issue. There will be a minor increase in the pill  
7 burden to the participants of this trial; however, this is not a major issue since the  
8 intervention is available as a single tablet that needs to be taken only once daily.

9  
10 Other ethical issues include contraception for all women of childbearing age during the course  
11 of the trial and additional clinic visits required for baseline assessments and dose titration  
12 (limited to only 40 and 80mg arms). For a subset of patients recruited to undertake the sub-  
13 study, it may involve additional patient time to undertake MRI/MRS scans. In the event that the  
14 study is discontinued, participants will be treated according to standard clinical care.

#### 15 16 **Ethical and Regulatory approvals**

17 The study, this protocol and related documents has been approved by the National  
18 Research Ethics Service Committee North West – Liverpool Central (Ref: 12/NW/0214).

19  
20 This study fall within the remit of the EU Directive 2001/20/EC, transposed into UK law as  
21 the UK Statutory Instrument 2004 No 1031: Medicines for Human Use (Clinical Trials)  
22 Regulations 2004 as amended. This trial has been registered with the Medicines and  
23 Healthcare Products Regulatory Agency (MHRA) and has been granted a Clinical Trial  
24 Authorisation (04196/0024/001-0001). The EUDRACT number is 2012-000935-18.

#### 25 26 **DATA COLLECTION AND TRIAL MONITORING**

##### 27 28 **Data collection**

29  
30 Data management procedures for the trial will be developed and overseen by the CTRC,  
31 University of Liverpool. The CTRC will provide training, essential documentation, and user  
32 support to the study centres, and monitoring, if triggered by an incident or where appropriate.  
33 All primary data will be entered into the study CRF for this study. Each participant will be  
34 assigned a unique screening number at the start of the assessment, which will be recorded  
35 on the consent form and the baseline assessment CRF and will be written on all other  
36 documents used to record participant data. All original CRFs will be returned to the CTRC.  
37 For the participant treatment diaries, the participant initials and randomisation number will be

1 clearly labelled on all documents. The laboratory read-outs will be obtained for blood, urine  
2 samples and for the body fat distribution sub-study from automated equipment. These will be  
3 uploaded securely to the central trial database.

4

## 5 **Trial monitoring**

6

7 Trial monitoring procedures for this study is based on a risk assessment conducted by the  
8 CTRC, University of Liverpool. Guidance issued by the MRC, Department of Health and the  
9 MHRA on risk-adapted approaches to the management of CTIMPs propose a three-level  
10 categorisation for the potential risk associated with an IMP[49]. In this study telmisartan is  
11 used outside the manufacturer's indication; therefore the IMP here is categorised as *Type B:*  
12 *'somewhat higher than that of standard medical care'*. This level of risk will inform the risk  
13 assessment, regulatory requirements, nature and extent of the monitoring, and the  
14 management processes used in the trial.

15

## 16 **Central Monitoring**

17 Data stored at CTRC will be checked for missing or unusual values and checked for  
18 consistency within participants over time. Any suspect data will be returned to the site in the  
19 form of data queries and sites are expected to respond to these queries with an  
20 explanation/resolution to the discrepancies. There are a number of monitoring features in  
21 place at the CTRC to ensure reliability and validity of the trial data.

22

## 23 **Clinical Site Monitoring**

24 CTRC personnel may need direct access to primary data such as patient records and  
25 laboratory reports; since this affects the patient's confidentiality, this fact is included on the  
26 patient information sheet. Individual participant medical information obtained as a result of  
27 this study is considered confidential and disclosure to third parties is prohibited. Medical  
28 information may be given to the participant's medical team and all appropriate medical  
29 personnel responsible for the participant's welfare. The only identifiable data transferred is  
30 the consent form and this is disclosed in the patient information sheet and consent form. The  
31 CTRC will preserve the confidentiality of participants taking part in the study and The  
32 University of Liverpool is registered as a Data Controller with the Information Commissioners  
33 Office.

## 34 **Trial Management and Oversight**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

*Trial Management Group (TMG)*

The TMG will be responsible for the day-to-day running and management of the trial and will meet as a minimum approximately 10 times a year. The TMG will comprise of the Chief Investigator, other lead investigators (clinical and non-clinical) and members of the trial coordinating centre (CTRC).

*Trial Steering Committee (TSC)*

The TSC will meet at least once annually and will provide overall supervision for the trial and provide advice through its independent Chairperson. The ultimate decision for the continuation of the trial lies with the TSC. The TSC will consist of an independent chairperson (with clinical expertise in HIV), two independent statisticians with expertise in adaptive trial design and medical statistics, a user representative, the investigators, representatives of the research networks, sponsors and principal investigators.

*Independent Data and Safety Monitoring Committee (IDSMC)*

The IDSMC will meet at least once annually and will be responsible for reviewing and assessing recruitment, interim monitoring of safety and effectiveness, trial conduct and external data. The IDSMC will provide a recommendation to the TSC concerning the continuation of the study. The IDSMC will consist of an independent chairperson (with clinical expertise in HIV) and two independent members: one who is an expert in the field of HIV lipodystrophy, and one who is an expert in medical statistics and adaptive trial design. Terms of reference for any of the above committees are available on request from the CTRC, University of Liverpool.

**NOTIFICATION OF AMENDMENTS**

Any amendments made to the study including protocol amendments will be communicated to the appropriate agencies for approval prior to implementation. All substantial amendments made will be notified to the REC and the MHRA for their approval; substantial amendments will also be notified to the sponsor and all participating research sites. All substantial and non-substantial amendments as well as respective regulatory approvals will be provided electronically via the Integrated Research Application System (IRAS) to the lead Comprehensive Local Research Networks who will notify the principal investigators at individual participating sites for local approval and implementation.

**TIME FRAME AND TRIAL STATUS**

1  
2 TAILoR is currently recruiting from 19 specialist HIV centres throughout the UK. The study  
3 has so far recruited 293 patients and has been given a no-cost extension to continue  
4 recruitment till the end of July 2015. Each participant is followed up for a total of 48 months.  
5 The total study period is 56 months.

6  
7  
8

## 9 **DISCUSSION**

10 Metabolic disease and insulin resistance continue to be a major problem in HIV-infected  
11 individuals; a recent longitudinal study observed an overall insulin resistance prevalence of  
12 21% (using a HOMA-IR cut-off>3.8) in HIV patients[50]. Given that HIV is now considered a  
13 chronic disease with an ageing population[51] and the fact that ageing further increase the  
14 susceptibility to age-related comorbidities such as metabolic and cardiovascular disease, the  
15 magnitude of this problem is likely to become even greater. This is exemplified by the fact  
16 that the prevalence of insulin resistance in HIV patients increases with age, ranging from 5%  
17 for <30 years to 30% in patients over 60 years of age[50]. Therefore there is a pressing need  
18 to develop or identify newer therapies to combat metabolic disease in this group of  
19 individuals; this trial will potentially address this need and may lead to the repositioning of  
20 telmisartan to treat metabolic disease.

21

22 Since the start of this trial, two smaller studies have already reported beneficial metabolic  
23 effects of telmisartan in cART-treated HIV patients. Whilst one study observed a reduction in  
24 HOMA-IR with 80mg telmisartan[52], the other did not find a reduction in HOMA-IR but  
25 observed a loss of total and subcutaneous fat with 40mg dose[53]. This clearly underlines  
26 the need for a well-powered trial to confirm the efficacy of telmisartan for reducing insulin  
27 resistance and this is met by the current study. The trial also utilises a novel adaptive design  
28 which will enable identification of the optimal dose of telmisartan, if ultimately it is found to  
29 elicit a statistically significant beneficial effect on insulin resistance. The adaptive design also  
30 allows stopping of the trial midway if none of the doses show a statistically significant effect  
31 after the interim analysis; this will reduce the duration of trial and result in cost saving.

32

33 Of course, we are assessing a surrogate marker (insulin resistance) as an outcome measure  
34 in this trial. Despite the fact there is a good relationship between insulin resistance and  
35 cardiovascular health[54 55], this represent a limitation of the trial. However, this is a phase  
36 IIb trial, and thus a surrogate marker as a primary outcome measure is justified, because a  
37 trial to show a reduction in cardiovascular end-points, will necessarily need to be large and  
38 would be reserved for a follow-on phase III design.

1 **Acknowledgements**

2

3 This project (Ref: 10/60/37) is funded by the Efficacy and Mechanism Evaluation (EME)  
4 Programme, an MRC and NIHR partnership. The manuscript has been reviewed by the EME  
5 and approved for publication.

6

7 We thank the Principal Investigators and research team of this multicentre study who are  
8 ideally suited to conduct this study due to their experience in the field of HIV and its  
9 management. We would also like to thank the members of the TSC and IDSMC for the trial  
10 oversight they provide. Finally we would like to thank all patients who are part of the study so  
11 far for contributing to this study.

12

13 SP is funded by the Wellcome Trust Institutional Strategic Support Fund (ISSF).

14

15 **List of Participating Centres:**

16 1. Prof Saye Khoo, The Royal Liverpool and Broadgreen University Hospitals NHS Trust,  
17 Liverpool.

18 2. Prof Margaret Johnson, Royal Free London NHS Foundation Trust, London.

19 3. Dr Barry Peters, Guy's and St Thomas' NHS Foundation Trust, London.

20 4. Dr Frank Post, King's College Hospital NHS Foundation Trust, London.

21 5. Dr Elbushra Herieka, The Royal Bournemouth and Christchurch Hospitals NHS  
22 Foundation Trust, Dorset.

23 6. Dr Satyajit Das, Coventry and Warwickshire Partnership NHS Trust, Coventry.

24 7. Dr Jane Minton, St James University Hospital, Leeds.

25 8. Prof Clifford Leen, Western General Hospital, Edinburgh.

26 9. Dr Duncan Churchill, Brighton and Sussex University Hospitals NHS Trust, Brighton.

27 10. Dr Fabiola Martin, YorClinic, York.

28 11. Dr David Chadwick, The James Cook University Hospital, Middlesbrough.

29 12. Dr Graeme Moyle, Chelsea and Westminster Hospital, St Stephens Aids Trust, London.

30 13. Dr Fabiola Martin, Harrogate District Hospital, Harrogate.

31 14. Dr Gabriel Schembri, Manchester Royal Infirmary, Manchester.

32 15. Dr Jonathan Ainsworth, North Middlesex University Hospital NHS Trust, London.

33 16. Dr Mark Gompels, Southmead Hospital, Bristol.

34 17. Dr Mas Chaponda, St Helens Hospital, Merseyside.

35 18. Dr David Loay, George Eliot Hospital NHS Trust, Nuneaton.

36 19. Dr Mayur Chauhan, The Newcastle Upon Tyne Hospitals NHS Foundation Trust.

37

38 **Author's contributions:** SP, MP, SK, PW, RKD, TJ, JW, JV were involved in the design of  
39 the study and preparation of the funding application. SP, MP, SK, PW, RKD, TJ, JW, JV,  
40 GK, MVH, CT and CS were involved in the development of protocol and protocol  
41 submission. SP and MP undertook drafting the manuscript. All authors have read the draft  
42 critically to make contributions and approved the final text.

43

44 **Competing Interests:** The authors declare that they have no competing interests.

45

46 **Ethics Approval:** The study, this protocol and related documents has been approved by the  
47 National Research Ethics Service Committee North West – Liverpool Central (Ref:  
48 12/NW/0214).

1 **Peer Review:** Peer reviewed for ethical and funding approval.

2  
3 **Disclaimer:** The views expressed in this publication are those of the author(s) and not  
4 necessarily those of the MRC, NHS, NIHR or the Department of Health.

5  
6 **References**

- 7 1. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education  
8 Program - Adult Treatment Panel III, International Diabetes Federation, and World  
9 Health Organization definitions of the metabolic syndrome as predictors of incident  
10 cardiovascular disease and diabetes. *Diabetes care* 2007;**30**(1):8-13 doi:  
11 10.2337/dc06-1414[published Online First: Epub Date]].
- 12 2. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition  
13 of lipodystrophy in HIV-infected adults: a case-control study. *Lancet*  
14 2003;**361**(9359):726-35
- 15 3. Potthoff A, Brockmeyer NH, Gelbrich G, et al. Lipodystrophy - a sign for metabolic  
16 syndrome in patients of the HIV-HEART study. *J Dtsch Dermatol Ges* 2010;**8**(2):92-8  
17 doi: 10.1111/j.1610-0387.2009.07330.x[published Online First: Epub Date]].
- 18 4. Paula AA, Falcao MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals:  
19 underlying mechanisms and epidemiological aspects. *AIDS research and therapy*  
20 2013;**10**(1):32 doi: 10.1186/1742-6405-10-32[published Online First: Epub Date]].
- 21 5. Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in  
22 HIV-infected patients: impact of different definitions of the metabolic syndrome. *Aids*  
23 2010;**24**(3):427-35 doi: 10.1097/QAD.0b013e328334344e[published Online First:  
24 Epub Date]].
- 25 6. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of  
26 diabetes mellitus in the multicenter AIDS cohort study. *Archives of internal medicine*  
27 2005;**165**(10):1179-84 doi: 10.1001/archinte.165.10.1179[published Online First:  
28 Epub Date]].
- 29 7. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in  
30 HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs  
31 (D:A:D) study. *Diabetes care* 2008;**31**(6):1224-9 doi: 10.2337/dc07-2013[published  
32 Online First: Epub Date]].
- 33 8. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of  
34 myocardial infarction. *The New England journal of medicine* 2007;**356**(17):1723-35  
35 doi: 10.1056/NEJMoa062744[published Online First: Epub Date]].
- 36 9. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-  
37 infected patients. *Aids* 2008;**22**(14):F17-24 doi:  
38 10.1097/QAD.0b013e32830fe35e[published Online First: Epub Date]].
- 39 10. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary  
40 atherosclerosis detected by coronary computed tomography angiography in HIV-  
41 infected men. *Aids* 2010;**24**(2):243-53 doi:  
42 10.1097/QAD.0b013e328333ea9e[published Online First: Epub Date]].
- 43 11. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated  
44 with combined antiretroviral therapy. *J Acquir Immune Defic Syndr* 2009;**50**(5):499-  
45 505 doi: 10.1097/QAI.0b013e31819c291b[published Online First: Epub Date]].
- 46 12. Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER  
47 stress in human adipocytes. *Biochem Biophys Res Commun* 2009;**386**(1):96-100 doi:  
48 10.1016/j.bbrc.2009.05.148[published Online First: Epub Date]].
- 49 13. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin  
50 sensitivity in healthy volunteers. *Aids* 2007;**21**(16):2183-90 doi:  
51 10.1097/QAD.0b013e32826fbc54[published Online First: Epub Date]].

- 1 14. Palacios R, Merchante N, Macias J, et al. Incidence of and risk factors for insulin  
2 resistance in treatment-naive HIV-infected patients 48 weeks after starting highly  
3 active antiretroviral therapy. *Antiviral therapy* 2006;**11**(4):529-35
- 4 15. Bernal E, Masia M, Padilla S, Ramos JM, Martin-Hidalgo A, Gutierrez F. [Insulin  
5 resistance in HIV-infected patients receiving long-term therapy with efavirenz,  
6 lopinavir/ritonavir and atazanavir]. *Medicina clinica* 2007;**129**(7):252-4
- 7 16. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose  
8 tissue volume with insulin resistance in control and HIV-infected subjects in the  
9 FRAM study. *J Acquir Immune Defic Syndr* 2007;**46**(3):283-90
- 10 17. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine  
11 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse  
12 transcriptase inhibitors. *Antiviral therapy* 2005;**10**(2):207-13
- 13 18. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on  
14 adipocyte lipid metabolism and survival alter the expression and secretion of  
15 proinflammatory cytokines and adiponectin in vitro. *Antiviral therapy* 2004;**9**(6):911-  
16 20
- 17 19. Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. *The*  
18 *Annals of pharmacotherapy* 2004;**38**(3):448-57 doi: 10.1345/aph.1D081[published  
19 Online First: Epub Date]].
- 20 20. McGoldrick C, Leen CL. The management of dyslipidaemias in antiretroviral-treated HIV  
21 infection: a systematic review. *HIV medicine* 2007;**8**(6):325-34 doi: 10.1111/j.1468-  
22 1293.2007.00480.x[published Online First: Epub Date]].
- 23 21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and  
24 death from cardiovascular causes. *The New England journal of medicine*  
25 2007;**356**(24):2457-71 doi: 10.1056/NEJMoa072761[published Online First: Epub  
26 Date]].
- 27 22. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-  
28 associated lipodystrophy syndrome: a meta-analysis of randomized trials. *BMC*  
29 *infectious diseases* 2010;**10**:183 doi: 10.1186/1471-2334-10-183[published Online  
30 First: Epub Date]].
- 31 23. Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in  
32 nondiabetic patients with essential hypertension. *Metabolism: clinical and*  
33 *experimental* 2006;**55**(9):1159-64 doi: 10.1016/j.metabol.2006.04.013[published  
34 Online First: Epub Date]].
- 35 24. Younis F, Stern N, Limor R, Oron Y, Zangen S, Rosenthal T. Telmisartan ameliorates  
36 hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic  
37 hypertensive rats via peroxisome proliferator activator receptor-gamma activation.  
38 *Metabolism: clinical and experimental* 2010;**59**(8):1200-9 doi:  
39 10.1016/j.metabol.2009.11.013[published Online First: Epub Date]].
- 40 25. Foryst-Ludwig A, Hartge M, Clemenz M, et al. PPARgamma activation attenuates T-  
41 lymphocyte-dependent inflammation of adipose tissue and development of insulin  
42 resistance in obese mice. *Cardiovascular diabetology* 2010;**9**:64 doi: 10.1186/1475-  
43 2840-9-64[published Online First: Epub Date]].
- 44 26. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB,  
45 Mandarim-de-Lacerda CA. Comparative effects of telmisartan, sitagliptin and  
46 metformin alone or in combination on obesity, insulin resistance, and liver and  
47 pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. *Clinical science*  
48 (London, England : 1979) 2010;**119**(6):239-50 doi: 10.1042/cs20100061[published  
49 Online First: Epub Date]].
- 50 27. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in  
51 type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. *Journal*  
52 *of clinical pharmacy and therapeutics* 2007;**32**(3):261-8 doi: 10.1111/j.1365-  
53 2710.2007.00820.x[published Online First: Epub Date]].
- 54 28. Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M. Effects of telmisartan on  
55 adiponectin levels and body weight in hypertensive patients with glucose intolerance.



- 1 Metabolism: clinical and experimental 2008;**57**(10):1473-8 doi:  
2 10.1016/j.metabol.2008.05.019[published Online First: Epub Date]].
- 3 29. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor  
4 blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic  
5 steatohepatitis. *World journal of gastroenterology : WJG* 2009;**15**(8):942-54
- 6 30. Rizos CV, Millionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combined with  
7 olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek  
8 adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-  
9 week, randomized, open-label, prospective study. *Clinical therapeutics*  
10 2010;**32**(3):492-505 doi: 10.1016/j.clinthera.2010.03.018[published Online First:  
11 Epub Date]].
- 12 31. Chujo D, Yagi K, Asano A, et al. Telmisartan treatment decreases visceral fat  
13 accumulation and improves serum levels of adiponectin and vascular inflammation  
14 markers in Japanese hypertensive patients. *Hypertension research : official journal of*  
15 *the Japanese Society of Hypertension* 2007;**30**(12):1205-10 doi:  
16 10.1291/hypres.30.1205[published Online First: Epub Date]].
- 17 32. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in  
18 individuals with the metabolic syndrome. *Journal of hypertension* 2007;**25**(4):841-8  
19 doi: 10.1097/HJH.0b013e3280287a83[published Online First: Epub Date]].
- 20 33. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for  
21 vascular events. *The New England journal of medicine* 2008;**358**(15):1547-59 doi:  
22 10.1056/NEJMoa0801317[published Online First: Epub Date]].
- 23 34. Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors activate the adipocyte renin  
24 angiotensin system. *Antiviral therapy* 2010;**15**(3):363-75 doi:  
25 10.3851/imp1533[published Online First: Epub Date]].
- 26 35. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. *World journal of*  
27 *diabetes* 2010;**1**(2):36-47 doi: 10.4239/wjd.v1.i2.36[published Online First: Epub  
28 Date]].
- 29 36. Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of  
30 randomized head-to-head trials. *International journal of cardiology* 2012;**156**(1):92-6  
31 doi: 10.1016/j.ijcard.2011.11.070[published Online First: Epub Date]].
- 32 37. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J. Microalbuminuria and  
33 hypertension in HIV-infected patients: a preliminary study of telmisartan. *European*  
34 *review for medical and pharmacological sciences* 2012;**16**(4):491-8
- 35 38. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to  
36 body adiposity: a magnetic resonance imaging and proton magnetic resonance  
37 spectroscopy study. *Gut* 2005;**54**(1):122-7 doi: 10.1136/gut.2003.036566[published  
38 Online First: Epub Date]].
- 39 39. Rico-Sanz J, Thomas EL, Jenkinson G, Mierisova S, Iles R, Bell JD. Diversity in levels of  
40 intracellular total creatine and triglycerides in human skeletal muscles observed by  
41 (1)H-MRS. *Journal of applied physiology (Bethesda, Md. : 1985)* 1999;**87**(6):2068-72
- 42 40. Dunnett C. Selection of the best treatment in comparison to a control with an application  
43 to a medical trial. In: Santer T, & Tamhane, AC ed. *Design of Experiments: Ranking*  
44 *and Selection*. . New York: Marcel Dekker, 1984:47-66.
- 45 41. Magirr D JT, Whitehead J. . A generalized Dunnett test for multi-arm multistage clinical  
46 studies with treatment selection. *Biometrika* 2012;**99**(2):494-501 doi:  
47 10.1093/biomet/ass002[published Online First: Epub Date]].
- 48 42. Whitehead J, Jaki T. One- and two-stage design proposals for a phase II trial comparing  
49 three active treatments with control using an ordered categorical endpoint. *Statistics*  
50 *in medicine* 2009;**28**(5):828-47 doi: 10.1002/sim.3508[published Online First: Epub  
51 Date]].
- 52 43. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and  
53 event time data. *Biostatistics (Oxford, England)* 2000;**1**(4):465-80 doi:  
54 10.1093/biostatistics/1.4.465[published Online First: Epub Date]].

- 1 44. Williamson PR, Kolamunnage-Dona R, Philipson P, Marson AG. Joint modelling of  
2 longitudinal and competing risks data. *Statistics in medicine* 2008;**27**(30):6426-38  
3 doi: 10.1002/sim.3451[published Online First: Epub Date]].
- 4 45. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in  
5 randomised controlled trials of complex interventions. *Statistical methods in medical*  
6 *research* 2010;**19**(3):237-70 doi: 10.1177/0962280209105014[published Online First:  
7 Epub Date]].
- 8 46. NIH. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse  
9 Events, Version 1.0 December, 2004; Clarification August 2009. 2004
- 10 47. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered  
11 telmisartan in healthy young and elderly volunteers and in hypertensive patients. *The*  
12 *Journal of international medical research* 2000;**28**(4):149-67
- 13 48. Stangier J, Su CA, Schondorfer G, Roth W. Pharmacokinetics and safety of intravenous  
14 and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment  
15 compared with healthy volunteers. *J Clin Pharmacol* 2000;**40**(12 Pt 1):1355-64
- 16 49. Depart of Health MRC, Medicines and Healthcare Products Regulatory Agency Clinical  
17 Trials Working Group.  
18 Risk\_adapted\_approaches\_to\_the\_management\_of\_clinical\_trials\_of\_investigational  
19 \_medicinal\_products.pdf. 2011
- 20 50. Araujo S, Banon S, Machuca I, Moreno A, Perez-Elias MJ, Casado JL. Prevalence of  
21 insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving  
22 current antiretroviral drugs. *European journal of endocrinology / European Federation*  
23 *of Endocrine Societies* 2014;**171**(5):545-54 doi: 10.1530/eje-14-0337[published  
24 Online First: Epub Date]].
- 25 51. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease.  
26 *Lancet* 2013;**382**(9903):1525-33 doi: 10.1016/s0140-6736(13)61809-7[published  
27 Online First: Epub Date]].
- 28 52. Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, De Caterina R.  
29 Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive  
30 patients. *Antiviral therapy* 2011;**16**(5):639-45 doi: 10.3851/imp1809[published Online  
31 First: Epub Date]].
- 32 53. Lake JE, Tseng CH, Currier JS. A pilot study of telmisartan for visceral adiposity in HIV  
33 infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial.  
34 *PloS one* 2013;**8**(3):e58135 doi: 10.1371/journal.pone.0058135[published Online  
35 First: Epub Date]].
- 36 54. Ginsberg HN. Insulin resistance and cardiovascular disease. *J Clin Invest*  
37 2000;**106**(4):453-8 doi: 10.1172/jci10762[published Online First: Epub Date]].
- 38 55. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease  
39 development. *Nature reviews. Endocrinology* 2014;**10**(5):293-302 doi:  
40 10.1038/nrendo.2014.29[published Online First: Epub Date]].

41  
42  
43  
44  
45  
46  
47  
48  
49  
50

1 **Legend for Figure 1**

2

3 **Figure 1: Flow Diagram for TAILoR Trial**

4

5

6 **Figure legend:** The trial will be conducted in two stages. Stage 1 of the study is dose-  
7 ranging and patients will be randomised 1:1:1:1 to receive one of 3 doses of telmisartan or  
8 no intervention (control). An interim analysis will be performed when half of the planned  
9 maximum of 336 patients have been followed up for at least 24 weeks. Stage II of the study  
10 will depend on the results of interim analysis, which could be one of the three outcomes  
11 shown in the figure. All assessments will be carried out at baseline and at weeks 12, 24, and  
12 48 post-treatment with telmisartan, as well as in the control arm. For those who participate in  
13 the MRI/MRS sub-study, assessment will be at baseline and 24 weeks. TEL: Telmisartan

14

15

16